Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gelbchem LLC currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's prosecution is concentrated, involving 1 distinct examiner and 1 distinct art unit. This indicates that the current active filings are being reviewed within a specific technical department by a single examiner. For a biotechnology company, this concentration can simplify the management of intellectual property, as the legal strategy does not need to account for multiple examiner styles or differing art unit standards at this time.
SUSAN EMILY FERNANDEZ is the busiest examiner for Gelbchem LLC, with 1 busiest examiner pending office action. This single action accounts for the total of 1 pending office action for the portfolio. The presence of only 1 distinct examiner and 1 distinct art unit suggests a streamlined prosecution process for the company's current biotechnology matters. Practitioners can focus their efforts on addressing the specific concerns raised by this examiner, knowing that there are no other pending actions requiring attention in other areas of the patent office. This allows for a more targeted and efficient approach to securing patent rights.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FERNANDEZ, SUSAN EMILY | 1 | 52.5% | +60.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18431778 | METHODS AND COMPOSITIONS FOR ASSAYING BETA-HEXOSAMINIDASE ENZYMATIC ACTIVITY VIA MASS SPECTROMETRY | FERNANDEZ, SUSAN EMILY | 23d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18431778 | METHODS AND COMPOSITIONS FOR ASSAYING BETA-HEXOSAMINIDASE ENZYMATIC ACTIVITY VIA MASS SPECTROMETRY | FERNANDEZ, SUSAN EMILY | 23d overdue |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18431778 | METHODS AND COMPOSITIONS FOR ASSAYING BETA-HEXOSAMINIDASE ENZYMATIC ACTIVITY VIA MASS SPECTROMETRY | FERNANDEZ, SUSAN EMILY | 1651 | §102§103§112 | Non-Final OA | 23d overdue | Pending | Feb 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial